Hemmel Amrania
NationalityBritish
CitizenshipEngland
EducationPhD: Imperial College London
Scientific career
InstitutionsImperial College London

Hemmel Amrania is a UK-based scientist and former research fellow at Imperial College London.[1]

Career

His current research centers on the development biomarkers in cancer and digital pathology assisted with spectroscopy.[2] He holds an M.Sc from Imperial College London[3][4] and a postgraduate MPhil (diplôme d'étude approfondie) from École supérieure d'optique, Paris where he also worked at the CNRS in Orsay before moving back to Imperial College to pursue his PhD. During his doctoral studies he worked with Sir Nicholas Wright OBE at the Cancer Research UK Labs investigating the detection of cancer biomarkers using spectroscopy notably without the use of reagents. Later he worked at the Charing Cross Hospital medical oncology unit under Charles Coombes (oncologist) and Sami Shousha (pathologist) investigating prognostic markers for the guidance of adjuvant therapy in early stage breast cancer patients. Subsequently as a research fellow at Imperial College London he spent time at the University of Oxford Synchrotron facility to explore single cancer cell imaging. After his academic career he later founded Digistain,[5][6][7] a spin-out technology from Imperial College praised for its ability to streamline therapy decisions in early breast cancer eliminating the need for the costly shipment of biopsies to centralized laboratories for analysis as per the current standard of care.[8][9][10]

For his developmental work on Digistain he was awarded the Royal Society Innovation Prize, a Cancer Research UK Pioneer Award and an Innovate UK SMART award.[11]

Awards

  • Outstanding Research Prize at Imperial College London
  • Innovation & Entrepreneurship Challenge Imperial College and the Climate KIC Competition held by the Mayor of London[12]
  • Award for solving treatment delays in breast cancer[13][4]
  • Royal Society Innovation Prize
  • Cancer Research UK Pioneer Award
  • Innovate UK SMART Award[11]
  • Medilink Midlands Finalist[14]
  • Institute of Physics Innovation Award[11]

References

  1. ↑ "Home - Dr Hemmel Amrania PhD". www.imperial.ac.uk. Retrieved 2023-07-27.
  2. ↑ "How this AI tool for breast cancer can tell you if you need chemotherapy or not". The Indian Express. 2023-02-05. Archived from the original on 2023-02-05. Retrieved 2023-07-27.
  3. ↑ "'Smart drugs' epidemic as one in 12 adults admit taking them - with most trying them at work". The Telegraph. 2018-06-15. ISSN 0307-1235. Retrieved 2023-07-27.
  4. 1 2 "Samantha Womack opens up about her cancer diagnosis". 2023-05-12. {{cite journal}}: Cite journal requires |journal= (help)
  5. ↑ "Optica Publishing Group". opg.optica.org. Retrieved 2023-07-27.
  6. ↑ "New "revolutionary" AI breast cancer diagnostic launched". Med-Tech Innovation. 2022-12-13. Retrieved 2023-07-27.
  7. ↑ "Rapid breast cancer screening technology could stop unnecessary chemotherapy | Imperial News | Imperial College London". Imperial News. 2022-10-17. Retrieved 2023-07-27.
  8. ↑ "New "revolutionary" AI breast cancer diagnostic launched". www.curetalent.co.uk. Retrieved 2023-07-27.
  9. ↑ "GDP unexpectedly falls, Bank of England stands firm and consumer confidence drops". Sky News. Retrieved 2023-07-27.
  10. ↑ "New revolutionary AI breast cancer diagnostic launched". Medical Buyer. 2022-12-14. Retrieved 2023-07-27.
  11. 1 2 3 "2022 Business Start-Up Award winner: Digistain". www.iop.org. Retrieved 28 July 2023.
  12. ↑ "Digistain: We Save Patients From Avoidable Chemotherapy". Y Combinator. Retrieved 2023-07-27.
  13. ↑ "Research, enterprise and education excellence recognised by Institute of Physics". Mirage News. Retrieved 2023-07-27.
  14. ↑ "Medilink Midlands announces awards finalists". Med-Tech Innovation. 2023-01-30. Retrieved 2023-07-27.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.